Intercept Pharmaceuticals Concludes Public Trading Chapter

The publicly traded journey of Intercept Pharmaceuticals has reached its conclusion. Following its complete acquisition by Italian pharmaceutical company Alfasigma S.p.A., the biotechnology firm’s shares are no longer available on public exchanges. Financial data platforms now classify the stock as an inactive instrument, confirming that public market activity has ceased entirely.

Acquisition Finalizes Corporate Transition

On November 8, 2023, Alfasigma executed the final phase of its takeover strategy, acquiring Intercept Pharmaceuticals in full. The transaction involved a cash payment of $19 per share, amounting to a total deal value of approximately $794 million. From that date forward, Intercept began operating as a wholly-owned subsidiary of Alfasigma, marking the end of its independent presence on public markets.

Market Exit Completes Corporate Evolution

The acquisition triggered immediate consequences for the company’s stock market status. Intercept’s common shares were formally removed from NASDAQ listing, with this delisting representing the definitive conclusion of trading operations. The classification as an inactive instrument across financial information services provides final confirmation: the security has lost all market liquidity and trading functionality.

Should investors sell immediately? Or is it worth buying Intercept?

Key Transaction Details:
* Final acquisition date: November 8, 2023
* Shareholder compensation: $19 per share in cash
* Exchange status: Delisted from NASDAQ
* Current trading availability: No public market access

For former shareholders, the acquisition process resulted in the automatic conversion of their holdings into cash at the specified $19 per share valuation. Any speculation regarding future price movements or current valuation assessments has become irrelevant—the era of Intercept as a publicly traded entity has permanently concluded.